Department of Cancer Biology

Shi-He Liu, M.D.

Assistant Professor
shi-he.liu@utoledo.edu

EDUCATION:

M.D.

1989

Medicine

Shandong Normal University, Jinan, China

Residency

1993

Hematology

Inst. of Hematology, Chinese Academy of Medical Sciences, Tianjin, China

M.S.

1996

Cell Immune Function in Chronic Myeloid Leukemia

Peking Union Medical College (PUMC) in Chinese Academy of Medical Sciences (CAMS), China

Post-Doc

2007

Surgery

Baylor College of Medicine, Houston, TX, USA

 

RESEARCH INTERESTS:

Therapies for pancreatic cancer are largely hindered by the lack of an effective delivery system. Applied nanotechnology has been revolutionized in the field of cancer therapeutics with immense potential owing to recent advancements in nanoparticles (NPs) based drug/small molecular delivery systems. Dr. Liu’s lab is focusing on nanodelivery system, utilizing state-of-the art technologies to develop an innovative smart exosome nanocarrier that would be able to overcome obstacles currently preventing the effective application of nanodelivery technology in the field of cancer biology. The research advances a safe, efficient, and stable nanodelivery system that actively targets pancreatic cancer and tumor microenvironment (TME), as well as minimalizes the clearance by mononuclear phagocytic system (MPS). Integration of previous studies in early detection and therapies for pancreatic cancer, Dr. Liu’s lab is going to utilize the novel delivery system to deliver super sensitive diagnostic biomarker for early detection of pancreatic cancer; deliver a combination of FDA approved drugs (simvastatin, digoxin and metformin) for BIRC5 targeted therapy for pancreatic cancer; and deliver a newly developed novel compound (c prime) for pancreatic cancer targeted therapy. The projects hold tremendous translational potential for cancer diagnosis and therapy.


FUNDING:

Ongoing Research Support
UTCOMLS Dean's Award
Smart Exosomes Enable Active PDAC Targeting nd Evading Mononuclear Phagocytotic System
07/01/2021-06/30/2022
Role:  PI

Completed funding
support

The Hirshberg Foundation Award
Developing a Potent Synthetic Reporter System for Earlier Detection, Accurate Quantification and Precise Localization of Pancreatic Cancer
02/01/2015-01/31/2016                        

R01CA095731, NCI
PDX-1 is a Therapeutic Target for Pancreatic Cancer
01/01/2008-12/31/2014
Role: Co-I

2R01 DK046441-11, NIH
Intraislet Communication in Surgically-Altered Pancreas
01/01/2003-12/31/2014
Role:  Co-I

PUBLICATIONS:  

pm

STUDENT OPENINGS: 
Currently accepting Ph.D., M.D./Ph.D., M.S. students

 

 

Last Updated: 9/29/21